ClinicalTrials.gg
Active, not recruitingNCT07215936Updated Oct 14, 2025

Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen

A Phase 2 interventional study of Arm A:Dose_dense Capecitabine in Colorectal cancer and Arm B : standard dose Capecitabine in Colorectal Cancer, sponsored by Sohag University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Sohag University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Colorectal Neoplasms with a site in Egypt — 15 open to participants now, 17 under way, 5 of them phase 3. Colorectal Neoplasms · Egypt.

Planned enrollment
8th of 31
100 · median 60
Started
2025
with 4 others
Phase 2
5 of 55
1 open now
Primary completion
2027-09
later than 14 of 16 live
Registered
46th of 55
by date
Lead sponsor
6 of 55
Sohag University

Among the 55 studies in Colorectal Neoplasms with a site in Egypt, this one is the 8th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 46th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 55 studies in Colorectal Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Colorectal Neoplasms with a site in Egypt, or all of them as a file.
02

Study summary

Dose_dense Capecitabine Schedule in colorectal cancers

Read the detailed description

Dose_dense Capecitabine schedule[7 days on_7days off] in colorectal cancer in comparison with standerd regimen

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients who diagnosed colorectal cancer Performance status ranging from 0 to 2 Both sexs

Exclusion criteria

Exclusion Criteria:

  • pateints with other Pateints who have other comorbid diseas
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Arm A :will receive capecitabine dose dense 1750 mg /m2 7days on treatment and 7 days off

    Drug: Arm A:Dose_dense Capecitabine in Colorectal cancer

  • Active comparator
    Arm B will receive capecitabine standard dose 1000mg/m2 2weeks on and 1 week off

    Drug: Arm B : standard dose Capecitabine

Interventions

  • DrugArm A:Dose_dense Capecitabine in Colorectal cancer

    Appling dose \_dense Capecitabine 1750mg/m2 for one week then one week off Cycle repeated every 2 weeks

  • DrugCapecitabineStudies of CapecitabineCapecitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pateints will receive capecitabine 1000 mg/m2 for 2 weeks then one week off

06

What researchers measure

Primary outcomes

  1. 1_Quality of life assessed through EORTC_QLQ_CR29 questionaire

    Time frame: 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2025
First posted
Oct 14, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07215936
Lead sponsor
Sohag University
Responsible party
Aliaa Alaa Abdelrahman (Assisstant lectular of clinical oncology, Sohag University) — Principal investigator
First posted
Oct 14, 2025
Start date
Sep 25, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion